ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

Key Takeaways

• Bayer will present 16 abstracts at ASCO 2026 covering six cancer types.
• NUBEQA head‑to‑head trial compares darolutamide with enzalutamide in CRPC.
• XOFIGO combined with cabozantinib or paclitaxel studied in RCC and breast cancer.
• New data includes sevabertinib for HER2‑mutant NSCLC and larotrectinib for NTRK‑fusion tumors.

Pulse Analysis

The American Society of Clinical Oncology’s 2026 meeting provides a global stage for oncology innovators, and Bayer is leveraging the forum to highlight the breadth of its pipeline. By presenting 16 abstracts across six tumor types, Bayer signals a strategic push to diversify its oncology portfolio beyond its established prostate‑cancer stronghold. The conference will be the first public venue for the ARACOG Phase II head‑to‑head trial, which pits NUBEQA against enzalutamide—a direct comparison that could redefine standard‑of‑care sequencing for castration‑resistant disease. Simultaneously, a post‑hoc PSA analysis from the larger ARANOTE study offers granular insights into patient subgroups, potentially guiding personalized androgen‑deprivation strategies.

Beyond prostate cancer, Bayer is testing the radiopharmaceutical XOFIGO in novel combination regimens. The RADICAL trial pairs radium‑223 with cabozantinib for renal‑cell carcinoma patients harboring bone metastases, while a separate Phase II study evaluates XOFIGO alongside paclitaxel in metastatic breast cancer. These investigations aim to exploit XOFIGO’s bone‑targeting mechanism while mitigating myelosuppression risks, a critical consideration given past safety signals when combined with other systemic agents. Positive outcomes could unlock new indications for a drug already approved for castration‑resistant prostate cancer, expanding its commercial footprint.

The broader agenda includes updates on sevabertinib for HER2‑mutant non‑small cell lung cancer and larotrectinib for NTRK‑fusion tumors, both of which address niche, genomically defined patient populations. By showcasing data across rare‑mutation and bone‑metastatic settings, Bayer positions itself at the intersection of precision oncology and radiopharmaceutical therapy. If the presented results confirm efficacy and manageable safety, the company may accelerate regulatory submissions and strengthen its competitive stance against other biotech firms targeting these high‑unmet‑need markets. The ASCO platform thus serves not only as a data‑sharing venue but also as a catalyst for future market expansion.